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Lung cancer is the leading cause of cancer related death, and the past years’ improved insight into underlying molecular events
has significantly improved outcome for specific subsets of patients. In particular, several new therapies that target protein kin-
ases have been implemented, and many more are becoming available. We have investigated lung cancer specimens for somatic
mutations in a targeted panel of 612 human genes, the majority being protein kinases. The somatic mutation profiles were cor-
related to profiles of immune cell infiltration as well as relapse-free survival. Targeted deep sequencing was performed on 117
tumour/normal pairs using the SureSelect Human Kinome kit (Agilent Technologies), with capture probes targeting 3.2 Mb of the
human genome, including exons and untranslated regions of all known kinases, kinase receptors and selected cancer-related
genes (612 genes in total). CD8 staining was determined using Ventana Benchmark. Survival analyses were performed using
SPSS. The number of mutations per sample ranged from 0 to 50 (within the 612 genes tested), with a median of nine. The prog-
nosis was worse for patients with more than the median number of mutations. A significant correlation was found between
mutations in one of selected DNA-repair genes and the total number of mutations in that tumour (p < 0.001). There was a signifi-
cant inverse correlation between the number of infiltrating stromal CD81 lymphocytes and the presence of EGFR mutations.
Lung cancer is a common cancer with a poor prognosis, and a
five-year survival rate of 15–20%. Most non-small cell lung can-
cer (NSCLC) patients have locally advanced or metastatic
disease (stage III/IV) at the time of presentation. Lung cancer is
responsible for approximately the same number of life years
lost as breast, prostate and colorectal cancers taken together.1
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During the past 10 years, there has been a change in treat-
ment algorithms for patients with NSCLC. For patients harbour-
ing activating mutations in the EGFR-gene, several clinical
studies have demonstrated a better efficacy of treatment with
EGFR tyrosine kinase inhibitors in terms of response rates, pro-
gression free survival and quality of life, when compared to stan-
dard chemotherapy.2 All patients with non-squamous NSCLC in
Norway are currently analysed for presence of EGFR-activating
mutations and ALK-aberrations in tumour biopsies.
Mutagenesis drives transformation of a normal cell to a
tumour. Mutations may be a result of endogenous processes
or of exposure to exogenous mutagens, in combination with
a failure of DNA repair pathways. Somatic mutations are
abundant in most cancers. However, most mutations do not
appear to play a role in the initiation of the cancer pheno-
type, but are rather indicative of a high mutation rate.3 The
majority of mutations are thus most likely bystander events,
that is, passenger mutations with no apparent fitness advan-
tage for the tumour clone. A minor set of mutations is on
the other hand thought to act as driver mutations, being
directly involved in the development or progression of the
tumour.4 The development of massively parallel sequencing
technologies has now enabled us to analyse the tumour
genome for substitutions, insertions and deletions with a
high sensitivity. The Cancer Genome Atlas (TCGA) project
has shown that lung carcinomas are among the tumours with
highest mutation frequency. Most of these mutations are pas-
senger mutations, contributing to a mutational signature
characteristic of tobacco smoking.5 Drugs targeting selected
mutations are currently being evaluated in clinical trials.
Most of these drugs are targeting protein kinases, thus we
have in this study focused on mutations in the “kinome,”
that is, in genes coding for kinases.
Stromal T-cell infiltration has prognostic impact in several
cancers. In colorectal cancers, assessment of T cells infiltrat-
ing the cancer tissue is used to create an “Immunoscore,” an
important supplement to the TNM-classification, designated
TNM-Immune (TNM-I). The prognostic value of this
immune-classification seems to be superior to the AJCC/
UICC TNM-classification alone.6 In NSCLC, the immune
stroma is recognised as highly important, with stromal T-cell
infiltration having a prognostic impact.7 In addition, immu-
notherapy has introduced a paradigm shift in lung cancer
treatment. The immune checkpoint inhibitors enable the
patient’s own T-cells to kill tumour cells. PDL1-expression is
being used as a predictive biomarker for response, but
PDL1-negative tumours still can have long-lasting effect of
treatment. An association between the number of non-
synonymous mutations and immunogenicity in lung carcino-
mas has been observed.8
Here, we present mutational analyses of 612 genes, includ-
ing all known kinases and kinase receptors in addition to
selected cancer-related genes, in 117 NSCLC tumours. We
have investigated the relationship of mutation rate to immu-
noscore and to the clinical course of the disease.
Material and Methods
Blood samples and tumour tissues were obtained from 117
operated lung cancer patients admitted to Oslo University
Hospital-Rikshospitalet in the period 2006–2011. The collected
tumor samples consisted of 93 adenocarcinomas, 2 large cell
carcinomas and 22 squamous cell carcinomas. Sixty patients
were female. One patient was diagnosed with metastases based
on pathology report, and was omitted from survival analyses.
Tumour tissue was snap frozen in liquid nitrogen and
stored at 2808C until DNA isolation. DNA was extracted
using MaxwellVR 16 DNA Purification Kits and a MaxwellV
R
16
instrument according to technical manual (Literature #
TM284)(http://www.promega.com). DNA from blood was
isolated using the Master Pure DNA purification Kit for
blood according to the DNA Purification Protocol (http://
www.epicentre.com).
Targeted resequencing was performed using the SureSelect
Human Kinome kit (Agilent Technologies), with capture
probes targeting 3.2 Mb of the human genome, including exons
and untranslated regions (UTRs) of all known kinases and
selected cancer-related genes (612). Library construction and in
solution capturing was performed following Agilent’s SureSe-
lectXT library construction kit and SureSelect Target enrich-
ment protocol, respectively. Sequencing was performed on an
Illumina Genome Analyzer using TruSeq SBS Kit v5 generating
paired-end reads of 75 bp in length. Base calling, demultiplex-
ing and quality filtering was performed using Illumina’s soft-
ware packages SCS2.8/RTA1.8 and Off-line Basecaller-v1.8. The
raw sequencing reads derived from tumour and control sam-
ples were subsequently processed in a computational pipeline
to identify and functionally annotate somatic DNA changes.
A variant calling pipeline was established to identify somatic
mutations in each tumour/control sample pair. This included
several steps: (i) alignment of sequence reads toward the refer-
ence genome (GRCh37 - including unlocalised/unplaced contigs
What’s new?
Lung carcinomas are among the tumours with highest mutation frequency. Here, the authors performed mutational analyses
of 612 genes–including all known kinases and kinase receptors–in 117 non-small cell lung cancer (NSCLC) tumours. They also
investigated the relationship of mutation rate to number of infiltrating lymphocytes and to the clinical course of the disease.
The number of mutations per sample varied, and the relapse-free survival was worse for patients with more than the median
number of mutations. Also, there was a significant inverse correlation between the number of infiltrating stromal CD81
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and decoy sequences) using BWA-mem,9 (ii) marking of poten-
tial PCR-derived duplicate reads using Picard (http://broadinsti-
tute.github.io/picard/), (iii) local realignment around indel sites
using GATK RealignerTargetCreator and IndelRealigner,10
(iv) base quality recalibration using GATK BaseRecalibrator, and
(v) somatic single nucleotide variant (SNV) and short insertion/
deletion (InDel) calling using Strelka and MuTect algo-
rithms.11,12 For SNVs, we only considered calls designated as
somatic by both MuTect and Strelka (InDels were called by
Strelka only). Our pipeline was recently part of a whole-genome
benchmarking exercise organized through ICGC, in which our
performance was assessed for SNV (precision5 0.90,
recall5 0.73) and InDel calling (precision5 0.71, recall5 0.70).13
To understand the functional role of identified variants,
all variants were subject to a computational annotation work-
flow including a modified version of ANNOVAR (release
2015Dec14, using Ensembl as the gene model), COSMIC
(known somatic cancer variants and Cancer Gene Census,
v76 February 2016), PFAM (protein domain information,
v27.0), UniProt KB (functional protein properties, release
2016_02), the Drug Gene Interaction Database (druggable
targets, version 2.0), Database of Curated Mutations (release
January 2016), and database of computational predictions of
effects of non-synonymous variants, v2.1.13–18
We used IntOGen (Integrative Onco Genomics) to iden-
tify cancer driver genes in our sample cohort. Considering
that a frequency-based approach to discover significantly
mutated genes is suboptimal in samples with low mutation
counts, IntOGen uses an approach by which a clustering and
functional bias among gene mutations (across the sample
cohort) indicates driver candidates.19
We have previously reported on the survival impact of
stromal CD8 expression (cytotoxic T-cells) including most of
the patients in this study (n5 107).7 In short, tissue micro-
arrays were used for determination of an immunoscore by
immunohistochemistry CD8 staining by Ventana Benchmark,
XT automated slide stainer (Ventana Medical System). By
light microscopy, the tissue cores were scored for the degree
of infiltration of CD81 lymphocytes. The percentages of
CD81 lymphocytes among all nucleated cells in the stromal
compartments were assessed. Scoring cut-off points at 5%,
25%, or 50% were used for each core. All samples were
anonymized and independently scored by two pathologists.
The mean score for duplicate cores from each individual was
calculated and the median stromal CD-8 score was used as
cut-off.
Time to relapse was calculated from the date of diagnosis
to the date of diagnosed local relapse, distant metastasis, or
lung cancer death with a maximum follow-up time of 80
months after surgery. Patients that died of other causes were
treated as censored. A p values< 0.05 was considered as sta-
tistically significant. The survival analyses were performed
using SPSS (PASW Statistics for Windows, version 18.0,
Chicago: SPSS). Survival curves and estimation of statistical
significance between the survival curves utilized the Kaplan-
Meier method and log rank test, respectively. A Cox regres-
sion model was applied for the multivariate survival analysis
using SPSS (v. 18). Factors included in the multivariate
model were stage, sex and histology. A p values< 0.05 was
considered statistically significant.
Results
Probes that targeted the human kinome were captured and
sequenced at 50–603 coverage in 117 tumour-control sample
pairs. The medians for allelic fraction and read depth at con-
fident variant sites were 0.2 and 84, respectively. The best
covered variant sites (read depth of 150) enabled detection of
variants with allelic fraction as low as 3–4%. In addition to
coding exonic sequences, the targeted regions included
canonical splice sites in introns, as well as UTRs. Intronic
sequences, except those included in splice sites, were excluded
from analysis. Each tumour sample had an accompanying
control sample (blood), which allowed the detection of point
mutations and insertions/deletions of somatic origin. Our
pipeline for somatic mutation detection relied on a consensus
between two different algorithms (MuTect and Strelka), a
strategy that performed well in a previous benchmarking
exercise.20 Only mutations called by both the algorithms were
thus included in the further analysis. The number of coding
mutations varied extensively between tumours, ranging from
0 to 50 (mean5 11, median5 9). Calculation of coding
mutations in the same genes (i.e., kinome) of TCGA lung
adenocarcinoma samples revealed similar numbers (mean
13.2, median 9).21 There was no significant difference in
number of mutations between men and women or between
tumours with different histological subtypes. Number of
mutations was significantly associated with packyears of
tobacco smoking (p5 0.009).
The TP53 gene and the TTN gene were the most frequently
mutated genes, the latter being a known artefact due to its large
size (Fig. 1a). The TP53 mutations were all validated by Sanger
sequencing where the sequences were aligned and analysed
using SeqScape v.2.5 according to the project template [TP53
accession nr. NM 000546 (TP53refNC000017.9NT010718.15)]
(http://www.appliedbiosystems.com.).
Through use of IntOGen, KRAS, EGFR, TP53 and STK11
were identified as significant cancer driver genes (Fig. 1b).
TP53 mutations were identified in 52 samples, of which two
had double mutations. KRAS was mutated in 28 samples (27
adenocarcinomas, one large cell carcinoma). Eight samples
(seven adenocarcinomas) were mutated in the STK11 gene.
Only adenocarcinomas were EGFR-mutated, with mainly
L858R mutations and exon 19 deletions.
Mutations in DNA repair genes
Twenty-seven samples had mutations in known DNA repair
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Figure 1. (a) Recurrence of somatically mutated genes. Shown are all mutated genes with a recurrence frequency >5 4% among all 117
samples. AD 5 Adenocarcinoma, SCC 5 Squamous Cell Carcinoma, LCC 5 Large Cell Carcinoma. (b) Frequency of somatic mutations for
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FANCL, CHEK1, CHEK2 and CLK2. There was a significant
correlation between mutations in one of these genes and the
total number of mutations (p< 0.001). Tumours with a
mutation in TP53, ATM or ATR had an increased number of
mutations when analysed separately (Fig. 2), whereas
tumours with mutations in the other repair genes did not
show a significant increase by themselves; however, the num-
ber of samples in these groups were small.
Immunoscore
The tumours were divided in three separate groups based
on an immunoscore reflecting the number of infiltrating
CD81 T-lymphocytes, as defined by Donnem et al.7 There
was no significant association between immunoscore and
the number of point mutations. However, when using the
median stromal CD8-score as cut-off (high score n5 58,
low score n5 49), there was a significant inverse correlation
between the number of infiltrating stromal CD81 lympho-
cytes and presence of EGFR mutations (r5 20.21, p5
0.029) (Pearson v2).
Survival
Patients with more than the median number of mutations in
their tumours had shorter relapse-free survival than patients
with sub-median mutation counts (Fig. 3, p5 0.056).
Multivariate analysis of relapse-free survival was per-
formed using Cox regression to study the influence of known
prognostic factors (histology, stage, sex). The number of
mutations was not significantly associated with survival in a
Cox-analysis with number of mutations as a continuous
Figure 2. Mutations in one of the DNA repair genes were significantly associated with a higher number of mutations. Mutations in TP53,
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variable (p5 0.60). However, the number of mutations
(over median) was found to be significantly associated with
time to progression after adjusting for clinical variables
(p5 0.021).
There was a tendency toward increased relapse-free sur-
vival for patients with high CD8-score (p5 0.10).
Discussion
By second-generation sequencing, we have confirmed that
lung cancers are highly heterogeneous in terms of somatic
mutation profiles, and that the number of mutations is asso-
ciated with patient survival.
An improved understanding of tumour emergence relies
on the identification of genes that drive carcinogenesis. Sev-
eral bioinformatics approaches have been proposed to iden-
tify driver genes, all with shortcomings and particular
biases.19 Given the limited number of mutations per tumour
kinome, we chose an approach (IntOGen) that emphasizes
enrichment of clustered and functionally biased mutations.
This algorithm has previously demonstrated its capability of
detecting cancer drivers.19
When applying the IntOGen algorithm on our dataset,
TP53, EGFR, KRAS, and STK11 were identified as significant
driver genes, as previously described.21 Despite extensive
efforts, no effective treatments targeting TP53 and KRAS
have been presented up to now. Conversely, targeted treat-
ment of mutated EGFR has changed the prospects for the
subset of patients with lung EGFR-mutation-positive lung
cancers. STK11 is a serine/threonine kinase and a tumour
suppressor and has been ranked as the third most frequently
mutated gene in lung cancers.22 It is implicated in cell polar-
ity, energy metabolism, apoptosis, cell cycle arrest and prolif-
eration. The mutations observed were in the protein kinase
domain, but are probably inactivating as STK11 is a tumour
suppressor. Other known genes involved in lung carcinogene-
sis, like ALK and ROS1, were also mutated in a small subset
of the tumours. However, these genes are usually changed by
inversions and translocations, not detected by our sequencing
analysis.
T-cells play pivotal effector-like roles in the human
immune system. They hamper tumour development, but
unfortunately tumours can prevent sustained T-cell responses
via immune checkpoints. The immune checkpoint-inhibitors
can restore T-cell involvement and lead to prolonged treat-
ment responses. Unfortunately, good predictive biomarkers
for response to checkpoint inhibitors are hitherto lacking.23
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There have been several reports indicating that the effect
of induced immune-response correlates with the number of
mutations, with the novel immunotherapeutic check-point
inhibitors having better efficacy on tumours with a high
number of mutations.8 EGFR-mutated tumours generally
have lower number of mutations.24 In our study, we found
significantly more infiltrating stromal CD81 T-cells in
tumours without EGFR mutations. This would be in accor-
dance with a higher number of immunogenic antigens in
tumours with a high number of mutations. In addition, this
is in accordance with the lack of CD81 lymphocyte response
in EGFR-mutant mice models and human tumours.25
Mutations in DNA repair genes would most often lead to
repair defects, which would in turn allow certain types of muta-
tions to accumulate. In our material, we find a significant
association between number of mutations and mutated DNA
repair genes. Whether the significantly higher number of muta-
tions is a consequence of dysfunctional DNA repair genes in
these cases has not been determined. Clearly, our study is limited
in size, so ruling out which genes in the DNA-repair pathway are
the most important should be studied more extensively, perhaps
revealing a correlation of mutation signature to specific defects.
A total of only 28 samples were mutated in the DNA repair
genes.
Despite the modest number of samples in our cohort, we
report a correlation between number of mutations and course
of disease. In the present era of evolving immune therapies,
we believe this to be an important insight, which needs more
attention in larger cohorts, and possibly with a further poten-
tial in the clinical setting.
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